BIO ESSENCE CORP.

BIOE ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $1.9M $323.9K $551.5K $621.6K $888.0K $958.7K
Cost of Revenue $469.2K $106.9K $274.1K $293.3K $589.7K $731.4K
Gross Profit $1.4M $217.1K $277.4K $328.3K $298.3K $227.3K
Gross Margin 75.3% 67.0% 50.3% 52.8% 33.6% 23.7%
Operating Expenses
Research & Development
SG&A Expense $497.8K $676.5K $345.6K $763.1K $1.1M $907.9K
Operating Income $900.0K $-459.4K $-345.6K $-511.1K $-857.5K $-832.6K
Operating Margin 47.4% -141.8% -62.7% -82.2% -96.6% -86.8%
Interest Expense $17.3K $14.1K $38.6K $41.9K
Pretax Income $897.0K $-1.6M $-403.0K $-525.4K $-644.3K $-592.5K
Income Tax Expense $800 $800 $1.6K $2.5K $3.3K $3.3K
Net Income $896.2K $-1.3M $-971.9K $-809.7K $-647.6K $-595.8K
Net Margin 47.2% -404.0% -176.2% -130.3% -72.9% -62.2%
EPS (Basic) $0.02 $-0.03 $-0.03 $-0.02 $-0.02 $-0.02
EPS (Diluted) $0.02 $-0.03 $-0.03 $-0.02 $-0.02 $-0.02
Shares Outstanding (Basic) 38.0M 38.0M 34.0M 33.0M 33.0M 33.0M
Shares Outstanding (Diluted) 38.0M 38.0M 36.0M 33.0M 33.0M 33.0M
Dividends Per Share